總結 (SUMMARY)
BoNT-A 仍是撫平臉部與頸部過度動作紋路、創造更悅目且年輕外觀的首選治療。無論單獨使用或與手術、軟組織填補，或汽化型與非汽化型雷射換膚合併使用，BoNT-A 治療既是藝術也是科學，其應用涵蓋臉部雕塑與強化，以及皮膚科的矯正。BoNT-A 的肌肉內注射也已成為多種以肌肉過度活動為特徵之疾患的第一線治療選項，例如斜視 (strabismus)、眼瞼痙攣 (blepharospasm)、半側顏面痙攣與頸部肌張力不全。此外，BoNT 能阻斷支配腺體組織或平滑肌之自主神經末梢釋放乙醯膽鹼與其他神經傳導物質的能力，已促成其用於多汗症、偏頭痛預防與雷諾氏現象。BoNT 使用簡便、微創且耐受性良好，具有令人印象深刻的安全紀錄，其適應症數量無疑將持續增加。
我們的電子書中另有補充圖片（存取碼見封面內頁）。
the treatment of glabellar frown lines. Dermatol Surg. 2010;36:2146–2154.11. Carruthers A, Carruthers J, Coleman 3rd WP, et al.
- Thomas AJ, Larson MO, Braden S, et al. Effect of 3 com-
New York: Marcel Dekker; 1994.2. Hexsel D, Brum C, do Prado DZ, et al. Field effect of two mercially available botulinum toxin neuromodulators on facial synkinesis: a randomized clinical trial. JAMA Facial Plast Surg. 2018;20:141–147.7. Monheit G, Pickett A. Basic science: abobotulinum toxin commercial preparations of botulinum toxin type A: a prospective, double-blind, randomized clinical trial. J Am Acad Dermatol. 2012;67:226–232.3. Kerscher M, Roll S, Becker A, Wigger-Alberti W. Com-
Multicenter, randomized, phase III study of a single dose of incobotulinumtoxinA, free from complexing proteins, in the treatment of glabellar frown lines. Dermatol Surg. 2013;39:551–558.12. Prager W, Bee EK, Havermann I, Zschocke I. Onset,
A. In: Carruthers A, Carruthers J, Dover JS, Alam M, eds. Procedures in Cosmetic Dermatology: Botulinum Toxin. 3rd ed. New York: Saunders Elsevier; 201326–34.8. Nettar KD, Yu KC, Bapna S, et al. An internally controlled, parison of the spread of three botulinum toxin type A preparations. Arch Dermatol Res. 2012;304:155–161.4. Hexsel D, Dal’Forno T, Hexsel C, et al. A randomized pilot longevity, and patient satisfaction with incobotulinumtoxinA for the treatment of glabellar frown lines: a single-arm, prospective clinical study. Clin Interv Aging. 2013;8:449–456.13. Frevert J, Sattler G. Basic science: xeomin. In: Carruthers double-blind comparison of the efficacy of onabotulinumtoxinA and abobotulinumtoxinA. Arch Facial Plast Surg. 2011;13:380–386.9. Karsai S, Raulin C. Current evidence on the unit equiva- study comparing the action halos of two commercial preparations of botulinum toxin type A. Dermatol Surg. 2008;34:52–59.5. Wilson AJ, Chang B, Taglienti AJ, et al. A quantitative
A, Carruthers J, Dover JS, Alam M, eds. Procedures in Cos-metic Dermatology: Botulinum Toxin. 3rd ed. New York: Saunders Elsevier; 2013:35–42.14. Carli L, Montecucco C, Rossetto O. Assay of diffusion of lence of different botulinumneurotoxinA formulations and recommendations for clinical practice in dermatology. Dermatol Surg. 2009;35:1–8.10. Sattler G, Callander MJ, Grablowitz D, et al. Noninferiority analysis of onabotulinumtoxinA, abobotulinumtoxinA, and incobotulinumtoxinA: a randomized, doubleblind, prospective clinical trial of comparative dynamic strain reduction. Plast Reconstr Surg. 2016;137: 1424–1433.
of incobotulinumtoxinA, free from complexing proteins, compared with another botulinum toxin type A in different botulinum neurotoxin type A formulations injected in the mouse leg. Muscle Nerve. 2009;40:374–380.
在已有身體狀況受損者身上使用的治療劑量。因此，FDA 要求所有 BoNT 產品變更安全性標示並加註黑框警語，以及實施風險評估與緩解策略（risk evaluation and mitigation strategy, REMS），包括一份說明治療相關風險的消費者指南。